SuperworthRoyalty Pharma RPRX
- Market cap
- $36.7B
- PE
- 36.3×
- 6y median 20.4×
- Forward PE
- 12.9×
- 6y median 9.3×
- Price to sales
- 14.5×
- EV/EBIT
- 30.2×
- Revenue, 12 months
- $2.5B
- +10% on a year ago
- Net margin
- 32.1%
- Free cash flow yield
- 7.5%
Royalty Pharma trades at 36.3× trailing earnings, pricier than 99% of the last ten years. Revenue was $2.5B over the last twelve months, up 10% on a year earlier with a 32% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $536.3M−7% | $596.1M+5% | $568M−17% | $537.3M−0% | $564.7M+5% | $593.6M−0% | $568.2M+0% | $578.7M+8% | $609.3M+8% | $622M+5% | $630.6M+11% | $674.1M+17% | |
| R&D | $50.5M+98% | $500K−99% | $500K+0% | $500K+0% | $500K−99% | $500K+0% | $50.5M+10000% | $300.5M+60000% | $50.5M+10000% | $50.5M+10000% | $39.8M−21% | $97.9M−67% |
| SG&A | $57.2M+13% | $59.2M−19% | $57.7M−33% | $54.7M+15% | $56.7M−1% | $67.6M+14% | $110.7M+92% | $179.8M+229% | $118.7M+109% | $164.3M+143% | $159.5M+44% | $161.9M−10% |
| $151.4M−21% | $612.9M | −$73.8M | $269.6M+8% | $735.1M+385% | $361.5M−41% | $534.2M | $209.8M−22% | $427.2M−42% | $388.4M+7% | $563M+5% | $133.1M−37% | |
| Interest expense | $46M−2% | $47.3M+1% | $44.2M−6% | $49M+4% | $66.5M+45% | $65.8M+39% | $65.3M+48% | $68.7M+40% | $79.6M+20% | $94.2M+43% | $93.7M+44% | $93.6M+36% |
| Pre-tax income | $122.1M−45% | $717.6M | −$4.3M | $194.4M−45% | $806.4M+561% | $334.4M−53% | $434.4M | $92.6M−52% | $444.2M−45% | $355.9M+6% | $468.3M+8% | $81.5M−12% |
| $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net income | $72.1M−49% | $494.3M | $4.8M−99% | $102M−55% | $544M+654% | $208.2M−58% | $239.3M+4909% | $32.2M−69% | $288.2M−47% | $214.2M+3% | $294.7M+23% | $17.9M−44% |
| $0.16−50% | $0.83 | $0.01−99% | $0.23−54% | $1.21+656% | $0.35−58% | $0.55+5400% | $0.07−70% | $0.67−45% | $0.38+9% | $0.67+22% | $0.04−43% | |
| 601.1M−1% | 597.5M | 597.5M−2% | 596.9M−2% | 592.7M−1% | 589.4M−1% | 578.1M−3% | 562.3M−6% | 559.6M−6% | 557.6M−5% | 556.8M−4% | 556.9M−1% |
Revenue: Q1 FY19 and Q1 FY20: 6 months less the 3 months printed beside them.
R&D: Q1 FY19 and Q1 FY20: 6 months less the 3 months printed beside them.
SG&A: Q1 FY19 and Q1 FY20: 6 months less the 3 months printed beside them.
Operating income: Q1 FY19 and Q1 FY20: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY19 and Q1 FY20: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY19 and Q1 FY20: 6 months less the 3 months printed beside them.
Income tax: Q1 FY19 and Q1 FY20: 6 months less the 3 months printed beside them.
Net income: Q1 FY19 and Q1 FY20: 6 months less the 3 months printed beside them.
EPS, diluted: 5 periods, Q1 FY20 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY20: share-days: the 6-month average less the second quarter's. 4 periods, Q4 FY20 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q3 FY26 | $884.8M | $876.8M to $892.9M | $1.18 | $1.15 to $1.21 | 5 |
| Q4 FY26 | $942M | $929.8M to $954.2M | $1.52 | $1.51 to $1.53 | 4 |
| Q1 FY27 | $869M | $850.8M to $895.6M | $0.98 | $0.96 to $1.02 | 1 |
| Q2 FY27 | $785.8M | $769.4M to $809.9M | $1.27 | $1.24 to $1.33 | 1 |
| Q3 FY27 | $963M | $942.9M to $992.5M | $1.31 | $1.27 to $1.36 | 1 |
| Q4 FY27 | $1B | $1B to $1.1B | $1.78 | $1.73 to $1.85 | 1 |
Peers
Companies in Healthcare nearest Royalty Pharma's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| RPRXRoyalty Pharma | $36.7B | 36.3× | 20.4× | 12.9× | 14.5× | +10% | 32.1% |
| RMDResMed | $36.5B | 24.2× | 37.3× | 20.8× | 6.5× | +10% | 26.9% |
| BIIBBiogen | $37B | 44.4× | 16.1× | 19.1× | 3.7× | +0% | 8.3% |
| CNCCentene | $34.7B | n/m | 20.7× | 15.0× | 0.2× | +14% | −2.5% |
| ZTSZoetis | $33.5B | 13.3× | 37.7× | 13.1× | 3.5× | +1% | 27.5% |
| MTDMettler-Toledo International | $33.5B | 37.6× | 36.5× | 33.9× | 8.1× | +7% | 21.9% |
| ILMNIllumina | $40.7B | 50.1× | 51.4× | 47.2× | 9.1× | +5% | 18.4% |
| GEHCGE HealthCare Technologies | $32.3B | 16.4× | 17.0× | 13.8× | 1.5× | +7% | 9.3% |
| ONCBeOne Medicines | $42.9B | 67.6× | 68.4× | 48.1× | 7.0× | +34% | 10.7% |
| IDXXIDEXX Laboratories | $44.1B | 39.4× | 55.0× | 35.9× | 9.7× | +13% | 25.0% |
| WATWaters | $44.6B | 113× | 29.2× | 29.2× | 9.6× | +52% | 3.6% |
| Peer median | $36.8B | 39.4× | 36.9× | 25.0× | 6.7× | +8% | 14.5% |
Investors who own it
Investors we follow who held Royalty Pharma at the end of Jun 30, 2026, from their 13F filings.
- Baillie GiffordBaillie Gifford0.5% of portfoliotrimmed
More on Royalty Pharma
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to book ratio
- Dividend yield
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #3of 53Healthcare stocks with the fastest expected revenue growth
- #7of 51Healthcare stocks with the lowest forward PE
Its groups
About
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .